Ashurst LLP advised Astorg Partners and Goldman Sachs Merchant Banking Division on the financing of the acquisition of the HRA Pharma group.
HRA Pharma, a pharmaceutical group founded in 1996, specialises in women's health and endocrinology.
Following the European Commission's approval of the merger on 21st January 2016, Astorg Partners and its co-investor, Goldman Sachs, gained control of the HRA Pharma group from its founders and the fund The Riverside Company in order to support the group's growth plan.
The transaction was finalised on 18th February 2016.
The team from Ashurst LLP Paris who advised on the financing aspects was composed of Stéphanie Corbière, partner, and Marie Roche and Margaux Baratte, associates.